Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPEP | Q07075 | 7/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.40 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.40 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.40 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29532309 | 0.91 | BACE1 (0.48) | ENPEPKEAP1BACE1PTPN1GRIN2D | |
| SCHEMBL29815405 | 0.88 | GRIN2D (0.49) | ENPEPKEAP1PTPN1GRIN2DGRIN3B | |
| SCHEMBL31410840 | 0.87 | ENPEP (0.45) | ENPEPKEAP1BACE1GRIN2DGRIN3B | |
| SCHEMBL29744994 | 0.84 | ENPEP (0.49) | ENPEP | |
| SCHEMBL30737969 | 0.83 | GLO1 (0.41) | KEAP1BACE1PTPN1GLO1 | |
| SCHEMBL30737960 | 0.82 | CCKBR (0.44) | GLO1 | |
| SCHEMBL29604170 | 0.82 | FOLH1 (0.42) | BACE1GLO1 | |
| SCHEMBL30974410 | 0.81 | GRIN2D (0.45) | ENPEPKEAP1BACE1PTPN1GRIN2D | |
| SCHEMBL30536331 | 0.81 | BACE1 (0.55) | ENPEPBACE1 | |
| SCHEMBL29683008 | 0.80 | MME (0.46) | ENPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116972-A1 | CROSS-SPECIES-SPECIFIC PSCAXCD3, CD19XCD3, C-METXCD3, ENDOSIALINXCD3, EPCAMXCD3, IGF-1RXCD3 OR FAPALPHAXCD3 BISPECIFIC SINGLE CHAIN ANTIBODY | AMGEN RES MUNICH GMBH (DE) | 2026-04-30 | — | — | US | disclosed |
| US-20250163179-A1 | CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY | AMGEN RESEARCH (MUNICH) GMBH (DE) | 2025-05-22 | — | — | US | disclosed |
| US-12281172-B2 | Cross-species-specific PSMAxCD3 bispecific single chain antibody | AMGEN RESEARCH (MUNICH) GMBH (DE) | 2025-04-22 | — | — | US | disclosed |
| US-20230357444-A1 | CROSS-SPECIES-SPECIFIC BINDING DOMAIN | AMGEN RES MUNICH GMBH (DE) | 2023-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116972-A1 | CROSS-SPECIES-SPECIFIC PSCAXCD3, CD19XCD3, C-METXCD3, ENDOSIALINXCD3, EPCAMXCD3, IGF-1RXCD3 OR FAPALPHAXCD3 BISPECIFIC SINGLE CHAIN ANTIBODY | MET, IGF1R, INHA | ENPEP 237/4885KEAP1 4780/4885BACE1 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.